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Objectives The purpose of this study was to determine the association of the F11 receptor (F11R) with human vascular disease.
Background A molecule identified as critical for platelet adhesion to a cytokine-inflamed endothelial surface in vitro is F11R.
The F11R is known to be expressed in platelets and endothelium and reported recently to be overexpressed in
atherosclerotic plaques.
Methods A novel enzyme-linked immunosorbent assay was developed for the measurement of soluble F11R in human
plasma. The F11R levels, along with a number of other biomarkers, were measured in 389 male patients with
known or suspected coronary artery disease (CAD) undergoing coronary angiography at a Veterans Administra-
tion Medical Center.
Results Patients with normal or nonobstructive disease (CAD angiographic score of 0), mild-to-moderate disease (score
of 1 to 3), and severe disease (score of 4 to 6) had median F11R plasma levels of 38.6 pg/ml (mean 260 
509.6 pg/ml), 45.2 pg/ml (mean 395.3  752.7 pg/ml), and 105.8 pg/ml (mean 629  831.7 pg/ml), respec-
tively (p  0.03). By multivariate analysis, the variables independently associated with CAD score were age, hy-
perlipidemia, chronic renal insufficiency, left ventricular function, and plasma F11R levels. The F11R was the
only biomarker that was independently associated with CAD score. Consistent with the previously reported ef-
fects of tumor necrosis factor (TNF)-alpha on F11R expression in cultured endothelial cells, F11R levels corre-
lated strongly with plasma TNF-alpha levels (r  0.84; p  0.0001).
Conclusions Plasma F11R is independently associated with the presence and severity of angiographically defined CAD. By
virtue of its strong correlation to plasma TNF-alpha, F11R may be an important mediator of the effects of in-
flammation on the vessel wall. Strategies that block F11R may represent a novel approach to the treatment of
human atherosclerosis. (J Am Coll Cardiol 2007;50:1768–76) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.051u
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ccepted May 28, 2007.tes significantly to the pathogenesis of atherosclerosis (1).
latelet adhesion to the inflamed endothelium triggers the
ormation of thrombi leading to atherosclerotic lesions (2).
key molecule identified as critical for platelet adhesion to
n activated endothelial surface is the F11 receptor (F11R)
3). The F11R is a novel cell adhesion molecule that is a
See page 1777
ember of the immunoglobulin superfamily and a human
rthologue of a murine cell adhesion molecule found in
ndothelial cells known as junctional adhesion molecule A,
r JAM-A (4,5). We have identified, sequenced, and cloned
he human gene for F11R/JAM-A and have demonstrated
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October 30, 2007:1768–76 Plasma F11R in Human Atherosclerosishat F11R plays a critical role in the adhesion of platelets to
ytokine-inflamed endothelial cells (3,5–7). We have also
ecently demonstrated very high levels of F11R/JAM-A
rotein and mRNA in the atherosclerotic plaques of pa-
ients with advanced aortic and peripheral vascular disease as
ell as in an animal model of atherosclerosis and reported
ata demonstrating a critical role for F11R in triggering
therogenesis (8).
Although these investigations point to a role for F11R in
he pathogenesis of atherosclerosis, there have been no
linical studies to establish a link between circulating plasma
11R and vascular disease in humans. The purpose of the
resent study was to determine whether plasma levels of
oluble F11R correlate with the presence or extent of
ngiographically defined coronary artery disease (CAD). To
his end, we developed a novel F11R enzyme-linked
mmunosorbent assay (ELISA) and report for the first
ime the detection, quantification, and characterization of
11R in humans. The results have implications for the
evelopment of novel therapeutic strategies targeting F11R
nd platelet adhesion and for the use of F11R as a
redictor/marker for the early diagnosis of CAD.
ethods
tudy design. This study was conducted at an urban
eterans Administration (VA) medical center and was
pproved by the local institutional review board. Written
nformed consent was obtained from all patients. Between
anuary 1999 and October 2002, 389 male patients with
nown or suspected CAD undergoing diagnostic coronary
ngiography were enrolled in the study. The only exclusion
riteria for participation in the study were active gastroin-
estinal bleeding or the presence of anemia, which was
efined as a hemoglobin concentration 8.0 g/dl. Clinical
nd demographic information was obtained by interview as
ell as review of computerized medical records. Fasting
lood was obtained from all patients at the time of angiog-
aphy for subsequent analysis.
lood sampling. After an overnight fast of at least 12 h,
lood was obtained from all patients enrolled in the study.
lood was collected from the arterial sheath (after a 5-ml
iscard) at the time of angiography but before the injection
f contrast material. Blood was immediately placed in
acutainer tubes, spun at 10 g for 20 min in a cold
entrifuge, and the plasma aliquoted into multiple 1.5-ml
ppendorf tubes. The samples were subsequently stored at
70°C until analysis at a later date.
aboratory methods. Aliquoted plasma samples stored at
70°C were thawed and, using commercially available
LISA kits, the levels of the following biomarkers were
easured: tissue inhibitor of metalloproteinase (TIMP)-1
EMD Biosciences, San Diego, Califorinia), matrix
etalloproteinase (MMP)-9 (EMD Biosciences), high-
ensitivity C-reactive protein (hs-CRP) (Life Diagnostics,
est Chester, Pennsylvania), plasminogen activator inhib- itor (PAI)-1 (Diapharma, West
hester, Ohio), regulated upon
ctivation, normal T-cell expressed
nd secreted (RANTES) (R&D
ystems, Minneapolis, Minne-
ota), tumor necrosis factor (TNF)-
lpha (R&D Systems), insulin
Linco Diagnostics, St. Charles,
issouri), and F11R (R&D Sys-
ems; and BD Biosciences, San
ose, California). The sensitivities
f the TIMP-1, MMP-9, hs-
RP, PAI-1, RANTES, TNF-
lpha, insulin, and F11R assays
ere 0.0096 ng/ml, 0.1 ng/ml,
.1 mg/l, 0.5 ng/ml, 15.6 pg/ml,
5.6 pg/ml, 2 U/ml, and 15.6
g/ml, respectively. The intra-
ssay coefficients of variation for
IMP-1, MMP-9, hs-CRP,
AI-1, RANTES, TNF-alpha,
nsulin, and F11R were 5.2%,
10%, 7.6%, 3.0%, 5.0%,
10%, 7.0%, and 10%,
espectively.
evelopment of ELISA for
11R. ANTIBODIES AND RE-
GENTS. Biotinylated antihuman
AM-A antibody, recombinant
uman JAM-A/Fc chimera,
treptavidin-horseradish peroxi-
ase (HRP) conjugate, buffers,
RP substrate and stop solution
ere purchased from R&D Sys-
ems. Bovine serum albumin
BSA) was obtained from Sigma (St. Louis, Missouri),
unc-Immuno Maxi Absorp 96-well plates were obtained
rom VWR (Bridgeport, New Jersey), and M.Ab.F11, an
11R/JAM-A monoclonal antibody developed and charac-
erized in our laboratory (3), was purchased from BD
harMingen Biosciences (Palo Alto, California).
REPARATIONOF REAGENTS FOR THE F11R ELISA. Aliquots
f recombinant human JAM-A/Fc chimera (50 g) were
econstituted with sterile 0.1% BSA–phosphate-buffered
aline (PBS) to a final concentration of 100 g/ml and
tored at 70°C. Freshly-prepared M.Ab.F11 was diluted
ith sterile PBS to a final concentration of 4 g/ml, and
iotinylated antihuman JAM-A antibody was diluted to a
nal concentration of 200 ng/ml with 0.1% BSA-PBS. The
tock solution of streptavidin-HRP conjugate was diluted
00 in 0.1% BSA-PBS. The substrate solution was
repared according to the manufacturer’s instructions 15
in before use, and the wash buffer was diluted 25 with
istilled H2O. Freshly prepared blocking solution (1% BSA
Abbreviations
and Acronyms
BSA  bovine serum
albumin
CAD  coronary artery
disease
CRI  chronic renal
insufficiency
ELISA  enzyme-linked
immunosorbent assay
ESR  erythrocyte
sedimentation rate
F11R  F11 receptor
HRP  horseradish
peroxidase
hs-CRP  high-sensitivity
C-reactive protein
JAM-A  junctional
adhesion molecule-A
LV  left ventricular
MI  myocardial infarction
MMP  matrix
metalloproteinase
PAI  plasminogen
activator inhibitor
PBS  phosphate-buffered
saline
RANTES  regulated upon
activation, normal T-cell
expressed and secreted
TIMP  tissue inhibitor of
metalloproteinase
TNF  tumor necrosis
factorn PBS) and stock solutions were stored at 70°C.
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Table 1 Baseline Characteristics Grouped by CAD Score
Characteristic
CAD Score 0
(Normal or Nonobstructive Disease)
n  74
CAD Score 1 to 3
(Mild to Moderate Disease)
n  276
CAD Score 4 to 6
(Severe Disease)
n  39
Total Population
n  389 p Value
Age, yrs, mean (SD) 61.7 (10.1) 66.0 (9.8) 67.4 (10.0) 67.7 (9.6) 0.0010
Family history of premature CAD, n (%) 15 (20.3) 66 (23.9) 15 (38.5) 96 (24.7) 0.0886
Diabetes mellitus, n (%) 29 (39.2) 119 (43.1) 21 (53.9) 169 (43.4) 0.3206
Hypertension, n (%) 57 (77.0) 231 (83.7) 37 (94.9) 325 (83.6) 0.0515
History of tobacco use, n (%) 59 (79.7) 226 (81.9) 31 (79.5) 316 (81.2) 0.8762
Active tobacco use, n (%) 27 (36.5) 84 (30.4) 9 (23.1) 120 (30.9) 0.3281
Hyperlipidemia, n (%) 29 (39.2) 154 (55.8) 30 (76.9) 213 (54.8) 0.0005
LDL, mean (SD) 107.6 (37.8) 106.6 (33.5) 103.9 (43.0) 106.6 (35.3) 0.4912
HDL, mean (SD) 39.8 (11.4) 38.8 (10.9) 36.4 (9.8) 38.8 (10.9) 0.5488
Total cholesterol, mean (SD) 172.5 (42.1) 174.6 (41.8) 168.8 (42.9) 173.6 (41.9) 0.9314
Triglycerides, mean (SD) 128.7 (97.9) 147.0 (97.8) 136.2 (82.7) 142.4 (96.4) 0.0958
BMI, mean (SD) 29.4 (5.9) 28.4 (5.5) 29.6 (6.4) 28.7 (5.7) 0.3584
Obesity, n (%) 24 (32.4) 97 (35.3) 15 (38.5) 136 (35.1) 0.8073
CHF on presentation, n (%) 27 (36.5) 63 (22.8) 12 (30.8) 102 (26.2) 0.0475
MI on presentation, n (%) 8 (10.8) 87 (31.5) 12 (30.8) 107 (27.5) 0.0017
CRI, n (%) 0 (0.0) 16 (5.8) 2 (5.1) 18 (4.6) 0.0609
ASA use, n (%) 60 (81.1) 237 (85.9) 34 (87.2) 331 (85.1) 0.5478
Beta-blocker use, n (%) 37 (50.0) 201 (72.8) 29 (74.4) 267 (68.6) 0.0006
ACE-I use, n (%) 42 (56.8) 167 (60.5) 27 (69.2) 236 (60.7) 0.4326
Statin use, n (%) 28 (37.8) 147 (53.3) 30 (76.9) 205 (52.7) 0.0004
Fibrate use, n (%) 1 (1.4) 13 (4.7) 2 (5.1) 16 (4.1) 0.4083
Prior CABG, n (%) 0 (0.0) 13 (4.7) 22 (56.4) 35 (9.0) 0.0001
LV function, mean (SD) 0.8554
0, 1 41 (55.4) 162 (58.7) 18 (46.2) 221 (56.8)
2, 3 25 (33.8) 106 (38.4) 14 (35.9) 145 (37.3)
Not reported 8 (10.8) 8 (2.9) 7 (18.0) 23 (5.9)
Troponin I* 0.0002
Mean (SD) 1.1 (3.6) 13.1 (55.3) 9.5 (23.1) 10.4 (47.3)
Median (IQR) 0.2 (0.2, 0.3) 0.3 (0.2, 2.8) 0.3 (0.2, 8.0) 0.3 (0.2, 1.7)
ESR* 0.1067
Mean (SD) 21.1 (18.5) 24.8 (24.0) 35.2 (33.2) 25.2 (24.4)
Median (IQR) 13.5 (7.0, 30.0) 16.0 (8.0, 36.0) 28 (10.0, 45.0) 16.0 (8.0, 36.0)
hs-CRP* 0.3392
Mean (SD) 17.4 (27.8) 24.4 (40.8) 32.3 (56.0) 23.8 (40.5)
Median (IQR) 7.7 (3.8, 15.5) 7.8 (3.8, 19.5) 9.8 (3.2, 32.4) 9.2 (3.8, 18.8)
PAI-1* 0.6227
Mean (SD) 40.3 (36.7) 43.3 (35.7) 45.6 (36.6) 42.9 (35.9)
Median (IQR) 31.7 (18.0, 53.4) 34.9 (19.0, 56.9) 36.1 (24.0, 54.6) 33.4 (19.0, 56.3)
MMP-9* 0.6597
Mean (SD) 26.9 (21.1) 27.4 (26.9) 23.0 (19.8) 26.9 (25.2)
Median (IQR) 20.0 (12.5, 32.0) 17.1 (12.4, 32.2) 19.3 (10.5, 26.7) 18.1 (12.3, 31.4)
TIMP-1* 0.3708
Mean (SD) 87.8 (40.4) 94.0 (47.5) 93.9 (41.9) 92.7 (45.6)
Median (IQR) 77.4 (63.6, 92.2) 81.7 (66.7, 102.0) 81.1 (70.8, 98.6) 81.1 (66.5, 100.9)
F11R* 0.0329
Mean (SD) 260.4 (509.6) 395.3 (752.7) 629.5 (831.7) 392.2 (725.2)
Median (IQR) 38.6 (18.9, 203.7) 45.2 (15.3, 289.2) 105.8 (31.2, 1132.3) 46.1 (16.8, 303.4)
TNF-alpha* 0.1292
Mean (SD) 134.4 (303.8) 175.8 (398.7) 326.9 (585.4) 182.6 (406.6)
Median (IQR) 14.5 (7.8, 58.0) 15.0 (7.8, 61.0) 21.1 (12.6, 314.4) 16.3 (7.8, 75.0)
Insulin* 0.3814
Mean (SD) 11.5 (8.2) 11.6 (2.1) 12.4 (10.4) 11.6 (11.3)
Median (IQR) 8.9 (6.2, 13.4) 8.2 (5.6, 13.6) 9.7 (6.3, 12.9) 8.4 (5.8, 13.5)
RANTES* 0.3555
Mean (SD) 3,935 (2,856) 4,878 (4,550) 4,074 (4,190) 4,620 (4,252)
Median (IQR) 3,155 (1,273, 5,814) 3,186 (1,489, 7,477) 3,069 (1,145, 5,360) 3,184 (1,408, 6,622)
Skewed distribution.
ACE-I  angiotensin-converting enzyme inhibitor; ASA  aspirin; BMI  body mass index; CABG  coronary artery bypass graft; CAD  coronary artery disease; CHF  congestive heart failure; CRI 
hronic renal insufficiency; ESR  erythrocyte sedimentation rate; F11R  F11 receptor; HDL  high-density lipoprotein; hs-CRP  high-sensitivity C-reactive protein; IQR  interquartile range; LDL 
ow-density lipoprotein; LV  left ventricular; MI  myocardial infarction; MMP  matrix metalloproteinase; PAI  plasminogen activator inhibitor; RANTES  regulated upon activation, normal T-cell
xpressed and secreted; SD  standard deviation; TIMP  tissue inhibitor of metalloproteinase; TNF  tumor necrosis factor.
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October 30, 2007:1768–76 Plasma F11R in Human AtherosclerosisERFORMANCE OF F11R ELISA. The Nunc-Immuno Maxi
bsorp 96-well plates were coated with M.Ab.F11 (4
g/ml), incubated at 23°C overnight, washed 3 times with
ash buffer, and incubated with 1% BSA-PBS for 2 h at
3°C. For preparation of the F11R standard curve, a series
f dilutions of the recombinant human JAM-A/Fc protein
n 0.1% BSA-PBS were prepared. Aliquots of these dilu-
ions and aliquots of undiluted patient plasma samples (100
l) were added to wells in triplicate. After a 2-h incubation
eriod, biotinylated antihuman JAM-A antibody (200 ng/
l) was added and the plates incubated for 1 h 45 min at
3°C. After washings, diluted streptavidin-HRP (1:400,
00 l/well) was added and the plates incubated for 30 min.
fter each step, the plates were washed 3 times with wash
uffer. The freshly prepared substrate solution (100 l/well)
as then added and the plates incubated for an additional
0 minutes. Absorption was measured at 450 nm within 30
in. Reagent controls were subtracted from the sample
alues.
ETERMINATION OF SERUM F11R LEVELS IN HEALTHY
ONTROLS. Fifteen control samples were obtained for the
etermination of basal levels of F11R from healthy adult
ale volunteers. These control donors were free of any
nown medical diseases or acute illnesses, and were not on
ny medications. Whole blood (10 ml) was obtained by
enipuncture of the anticubital vein. After clot formation
nd retraction, samples were centrifuged at 223 g for 10 min
t 22°C, and serum samples were collected and frozen at
20°C. The median serum level for this healthy control
roup was 36.0 pg/ml (mean 33.71  20.9 pg/ml).
efinition of risk factors and clinical syndromes. Diabe-
es was defined as clinically known and treated diabetes
ellitus. Patients were diagnosed as hypertensive if they
ere documented to have a blood pressure 140/90 mm
g on more than 2 occasions or were already on antihyper-
ensive therapy. Hyperlipidemia was diagnosed in patients
ho had been given lipid-lowering medication or had a
istory of total cholesterol levels 240 mg/dl (9). Smoking
as defined as the inhaled use of cigarettes, cigars, or pipes
n any quantity. Smokers were classified as former only if
hey had not smoked at all in the 6 months preceding the
ate of angiography. Obesity was defined as a body mass
ndex 30 kg/m2. Chronic renal insufficiency (CRI) was
efined as a serum creatinine 2.0 mg/dl. Congestive heart
ailure on presentation was defined as the presence of either
adiographic or clinical evidence of pulmonary venous con-
estion within the preceding 24 h of angiography. Myocar-
ial infarction (MI) on presentation was diagnosed by a
istory of chest discomfort and troponin I 1.0 ng/ml.
ngiographic scoring system. A previously described and
alidated angiographic scoring system was used for the
resent analysis (10). The scoring system was specifically
esigned to take into account both native vessel (including
eft main coronary artery) and bypass graft disease. It was
ased on the traditional definition of an angiographicallyignificant stenosis as one with a 50% obstruction and the
natomic territory subtended by the diseased artery or graft.
sing visual estimation of stenosis severity, angiograms
ere scored as follows. Any obstructive lesion 50% in 1 of
he 3 coronary arteries or their major (2.5 mm) branches
eceived a score of 1. Multiple obstructive lesions 50% in
single artery or one of its major branches still only received
score of 1, except in the case of a left dominant system. In
he case of a left-dominant system, an obstruction 50% in
he proximal portion of the left circumflex artery received a
core of 2. Similarly, in a left-dominant system, an obstruc-
ion50% in both a large obtuse marginal branch and a left
osterior descending artery (PDA) also received a score of 2.
n the other hand, an obstruction50% in a left-dominant
ystem that was isolated to either a left PDA or an obtuse
arginal (but not both) received a score of 1. An obstruc-
ion of 50% in the left main coronary artery received a
core of 2 in a right-dominant system and 3 in a left-
ominant system. A bypass graft with an obstructive lesion
50% received a score of 1. Patent grafts or those with an
bstructive lesion 50% received a score of 0.
Angiograms were scored by 2 angiographers working
ndependently. Any differences in interpretation (7%) were
ubsequently reconciled. The operators scoring the angio-
rams were blinded to the results of any subsequent labo-
atory analysis.
Left ventricular (LV) systolic function was assessed by
ontrast ventriculography and categorized as normal (ejec-
ion fraction [EF] 55%) or mildly (EF 45% to 54%),
oderately (EF 31% to 44%), or severely (EF 30%)
educed. These 4 categories of LV systolic function were
cored as 0, 1, 2, and 3, respectively.
Figure 1 Plasma F11R Levels as a Function of CAD Score
Results are presented as mean  SEM. There was a progressive and signifi-
cant increase in plasma F11 receptor (F11R) levels with an increasing coronary
artery disease (CAD) score when patients were grouped as having normal or
nonobstructive disease (score of 0), mild to moderate disease (score of 1 to
3), and severe disease (score of 4 to 6). p  0.0329 by the Wilcoxon rank-
sum test.
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Plasma F11R in Human Atherosclerosis October 30, 2007:1768–76tatistical methods. The study population was divided
nto 3 groups based on the CAD score as follows: 1) normal
r nonobstructive disease (CAD score 0); 2) mild to
oderate disease (CAD score 1 to 3); and 3) severe disease
CAD score 4 to 6).
Summary statistics for the continuous variables were
resented both as mean (with standard deviation) and as
edian (with interquartile range), and comparisons between
he 3 groups were performed with the nonparametric
Association of F11R With Cardiovascular Risk F
Table 2 Association of F11R With Cardiovas
Risk Factor Prese
Family history of premature CAD
n 87
Mean (SD) 305.1 (606.
Median (IQR) 31.8 (15.6
Diabetes mellitus
n 152
Mean (SD) 328.8 (609.
Median (IQR) 46.9 (17.2
Hypertension
n 291
Mean (SD) 408.0 (754.
Median (IQR) 46.1 (17.1
History of tobacco use
n 289
Mean (SD) 353.8 (609.
Median (IQR) 43.3 (16.3
Active tobacco use
n 113
Mean (SD) 310.9 (684.
Median (IQR) 31.1 (14.7
Obesity
n 122
Mean (SD) 377.3 (724.
Median (IQR) 45.9 (17.4
Hyperlipidemia
n 187
Mean (SD) 440.0 (761.
Median (IQR) 58.9 (16.8
ASA use
n 296
Mean (SD) 370.3 (708.
Median (IQR) 45.6 (17.9
Beta-blocker use
n 242
Mean (SD) 332.9 (630.
Median (IQR) 40.3 (16.1
ACE-I use
n 213
Mean (SD) 356.4 (738.
Median (IQR) 45.4 (17.4
Statin use
n 180
Mean (SD) 443.8 (772.
Median (IQR) 58.4 (16.9Abbreviations as in Table 1.ruskall-Wallis test. Data for the biomarkers were pre-
ented as median values, and as 25th and 75th percentile
alues. The associations between the biomarkers and both
11R and angiographic score were assessed with the Spear-
an rank correlation. Categoric data were summarized as
requencies and percentages, and the comparisons between
he 3 groups were performed with the Pearson chi-square
est or the Fisher exact test. The relations between plasma
11R levels and the cardiovascular risk factors such family
rs and Medication Use
r Risk Factors and Medication Use
Absent p Value
0.1148
263
421 (759.2)
) 52.3 (18.8, 367.1)
0.8851
198
440.9 (800.8)
) 45.9 (16.3, 476.2)
0.4786
59
314.4 (556.9)
) 46.2 (13.1, 234.6)
0.0344
61
574.3 (922.6)
) 97.6 (27.7, 636.9)
0.0284
237
431.0 (742.1)
) 56.6 (18.5, 387.2)
0.7954
227
402.0 (728.1)
) 47.2 (16.2, 357.6)
0.2196
163
337.5 (679.4)
) 40.3 (16.2, 203.7)
0.4114
54
512.5 (809.2)
) 66.5 (15.3, 948.7)
0.0449
108
525.2 (891.7)
) 83.7 (19.6, 665.5)
0.5838
137
448.0 (702.6)
) 54.8 (15.3, 684.4)
0.2647
170
337.7 (670.2)
) 42.8 (16.2, 234.6)acto
cula
nt
7)
, 186.4
8)
, 285.0
6)
, 344.8
8)
, 277.3
5)
, 194.9
7)
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5)
, 388.5
1)
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October 30, 2007:1768–76 Plasma F11R in Human Atherosclerosisistory, diabetes, hypertension, history of tobacco, active
obacco use, obesity, and hyperlipidemia were established
ith the Wilcoxon rank sum test.
The variables associated with CAD score were identified
ith univariate linear regression. Multivariate linear regres-
ion with backward selection of variables was used to
dentify those variables that were independently associated
ith CAD score. For the linear regression analyses, all
iomarkers (except troponin I) were log-transformed to
educe the skewness and kurtosis of the data.
All analyses used 2-sided tests with an overall significance
evel of alpha  0.05.
esults
aseline characteristics. A total of 389 male patients were
nrolled in the study. The baseline clinical and laboratory
haracteristics of the study population stratified by angio-
raphic score are shown in Table 1.
More advanced levels of CAD were seen in association
ith age, hyperlipidemia, CHF on presentation, MI on
resentation, prior coronary artery bypass graft surgery,
tatin use, beta-blocker use, higher troponin I levels, and
ypertension (borderline significance). Of the biomarkers
ssayed, only F11R levels were significantly associated with
ncreasing CAD score (Table 1). Specifically, patients with
ormal or nonobstructive disease (CAD score of 0), mild to
oderate disease (CAD score of 1 to 3), and severe disease
CAD score of 4 to 6) had median F11R plasma levels of
8.6 pg/ml (mean 260  509.6 pg/ml), 45.2 pg/ml (mean
95.3 752.7 pg/ml), and 105.8 pg/ml (mean 629 831.7
g/ml), respectively (p  0.03) (Fig. 1).
ssociation of F11R with clinical characteristics and
ther biomarkers. There was no association between
lasma F11R and any of the traditional cardiovascular risk
actors, with the exception of former and active tobacco use
Table 2). With respect to medication use, patients on
eta-blocker therapy had lower median F11R levels com-
ared with those not on such therapy (40.3 vs. 83.7 pg/ml,
espectively; p  0.05).
There was an inverse correlation between F11R levels and
he presence of MI. Patients presenting with MI had lower
edian plasma F11R levels compared with those patients
orrelation Analysis Betweenlasm F11R nd Oth r Biomarkers
Table 3 Correlation Analysis BetweenPlasma F11R and Other Biomarkers
Variable Spearman r Correlation p Value
TNF-alpha 0.84 0.0001
RANTES 0.12 0.0222
Troponin I 0.12 0.0408
PAI-1 0.15 0.0050
MMP-9 0.18 0.0006
TIMP-1 0.08 0.1401
hs-CRP 0.02 0.7691
Insulin 0.14 0.0093
ESR 0.11 0.0408ibbreviations as in Table 1.resenting with chest pain and no enzymatic evidence of
yocardial damage (34.3 vs. 58.4 pg/ml, respectively; p 
.0076).
With respect to plasma biomarkers, plasma F11R levels
ere positively associated with TNF-alpha, RANTES,
AI-1, MMP-9, insulin, and the erythrocyte sedimentation
ate (ESR) (Table 3). Of these positive correlations, the
ost significant was the correlation between F11R and
NF-alpha (r  0.84; p  0.0001), a prespecified analysis
ased on the basic science laboratory observation that
NF-alpha increases the expression of F11R/JAM-A in
ultured endothelial cells (Fig. 2) (6).
ssociation of F11R with angiographic score. The fol-
owing baseline clinical and laboratory characteristics were
ound to be associated with CAD score on univariate
nalysis: age, hypertension, active tobacco use, hyperlipid-
mia, CRI, plasma F11R, ESR, TIMP-1, hs-CRP, ratio of
IMP-1/MMP-9, LV function, beta-blocker use, and sta-
in use (Table 4). By multivariate analysis, the variables that
ere independently associated with CAD score were age,
yperlipidemia, CRI, LV function, beta-blocker use, and
lasma F11R (Table 5). Thus, F11R was the only biomar-
er that was independently associated with CAD score (p
.0091) (Table 5).
iscussion
he pathogenesis of atherosclerosis is multifactorial, but the
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Figure 2 Correlation Between
Plasma F11R and TNF-alpha Levels
There was a very strong and highly significant correlation (r  0.84; p 
0.0001) between the plasma levels of tumor necrosis factor (TNF)-alpha and
F11 receptor (F11R) in the entire cohort of patients, consistent with the in vitro
observations that TNF-alpha increases the expression of F11R in cultured
endotheial cells (6).nitiating process considered to be most essential is the
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Plasma F11R in Human Atherosclerosis October 30, 2007:1768–76eposition and oxidation of lipids in the vascular wall, with
he subsequent generation of a dysfunctional endothelium
1). Through the expression of a variety of well-
haracterized adhesion molecules (such as members of the
mmunoglobulin gene superfamily, the integrin family, and
he selectin family), dysfunctional endothelium attracts
irculating inflammatory cells into the subendothelial space
11,12). This now inflamed and dysfunctional endothelium
lso attracts platelets, but the pathways through which this
ccurs have been less well characterized. A key molecule
ecently identified as critical for platelet adhesion to in-
amed endothelium is F11R. The F11R is a cell adhesion
olecule, a member of the immunoglobulin superfamily
onstitutively expressed on the surface of human platelets,
hat has been demonstrated to play a role in platelet
ggregation, secretion, adhesion, and spreading (3,5–7).
he same molecule is also present at tight junctions of
ndothelial cells, where it is known as JAM-A and acts as a
ell adhesion molecule through homophilic interactions (4).
e have previously demonstrated that F11R plays a critical
ole in atherogenesis, providing over 50% of the force of the
dhesion of platelets to cytokine-inflamed endothelial cells
6). In addition, using molecular and immunofluorescence
echniques, we have recently demonstrated that F11R ex-
ression (both protein and mRNA) is increased in the
nivariate Analyses for CAD Score
Table 4 Univariate Analyses for CAD Score
Predictors of CAD Score p Value
Age/10 yrs 0.0001
CHF on presentation 0.8927
Hypertension 0.0010
Diabetes mellitus 0.1694
Family history of premature CAD 0.0887
Active tobacco use 0.0464
History of tobacco use 0.5045
Hyperlipidemia 0.0001
BMI 0.6301
Obesity 0.5315
Chronic renal insufficiency 0.0050
F11R 0.0470
ESR 0.0025
TIMP-1 0.0292
MMP-9 0.8798
PAI-1 0.2232
hs-CRP 0.0384
TIMP-1:MMP-9 ratio 0.0147
Troponin-I 0.2245
LV function 0.0035
TNF-alpha 0.1770
Insulin 0.9154
RANTES 0.4974
ASA use 0.5861
Beta-blocker use 0.0047
ACE-I use 0.0815
Statin use 0.0001
bbreviations as in Table 1.therosclerotic plaques of surgically excised human speci-
aens with advanced disease (8). However, to date there
ave been no clinical studies of circulating plasma F11R in
uman atherosclerosis.
In the present study, we show for the first time that
ignificantly higher levels of plasma F11R are found in
atients with more advanced angiographically documented
oronary artery disease. Furthermore, on multivariate anal-
sis this association is independent of other factors that
orrelated with atherosclerosis. Our findings are in accord
ith the growing body of evidence that the adhesion of
latelets to the vessel wall, with their subsequent activation
nd aggregation, contributes directly to the development
nd progression of atherosclerosis (1,13–16). Although
here is incontrovertible evidence supporting the role of
latelets in the acute thrombotic complications of athero-
clerosis (17,18), the concept that platelet adhesion to an
therosclerotic lesion may influence plaque progression and
tability has only recently received attention. For example,
oncurrent inhibition of cyclooxygenase (COX)-1 and -2,
ut not selective inhibition of COX-2, has been shown to
ause a significant reduction in experimental atherosclerotic
esions in the mouse (13). Huo et al (15). have also recently
emonstrated that circulating activated platelets promote
onocyte recruitment to atherosclerotic arteries and accel-
rate the formation of atherosclerotic lesions in mice defi-
ient in apolipoprotein E.
The findings of the present study are also in accord with
ur previously reported observation that TNF-alpha in-
reases the endothelial expression of F11R/JAM-A, leading
o increased adhesion of platelets which can in turn be
locked by specific inhibitory peptides of the action of F11R
6). In the present study, the correlation of F11R with
NF-alpha was highly significant and is the first clinical
ata to supports the experimental observations. Further-
ore, the absence of a correlation between TNF-alpha
nd the other tested biomarkers supports the specificity of
he TNF-alpha/F11R relationship. In total, these find-
ngs solidify the linkage between TNF-alpha, F11R
xpression, and the inflammatory process in human
therosclerosis.
The finding of a soluble fragment of the extracellular
omain of F11R, a cell surface-bound transmembrane
ultivariate Analysis for CAD Score*
Table 5 Multivariate Analysis for CAD Score*
Predictors of CAD Score p Value
Age/10 yrs 0.0001
Hyperlipidemia 0.0009
Chronic renal insufficiency 0.0088
LV function 0.0013
Beta-blocker use 0.0203
F11R 0.0091
Multivariate linear regression model involves backward stepwise elimination. Twenty-seven
linical and laboratory variables were initially studied (Table 4) by univariate analysis. Only those
redictors with p 0.05 were subsequently entered into a multivariate model, the results of which
re displayed here.
Abbreviations as in Table 1.
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October 30, 2007:1768–76 Plasma F11R in Human Atherosclerosiseceptor, in a circulating soluble form is not unique. One
otential mechanism is that F11R is shed from endothelial
ells and/or platelets through a pathway involving enzymatic
leavage at a site in close proximity to the membrane,
esulting in the release of the extracellular domain of F11R
nto the circulation. Such cleavage mechanisms have been
eported for L-selectin (19,20) and for the beta-integrin
lycoprotein IIIa (21), resulting in the shedding of frag-
ents of these molecules. Whether the platelets or the
ndothelium are the source of the circulating F11R is not
nown. The direct demonstration of soluble F11R shedding
uring or after adhesion of human platelets to cytokine-
nflamed endothelial cells is an area of continued basic
esearch on F11R.
Finally, our findings of an inverse correlation between
lasma F11R levels and the presence of MI may at first seem
ounterintuitive. However, it is conceivable that the pool of
nbound circulating soluble F11R is diminished in the
ontext of acute coronary syndromes by virtue of its binding
o activated platelets, inflamed endothelium, and leukocytes
22–24). Alternatively, the decreased levels of soluble F11R
rotein may relate to the release of proteases from activated
latelets that degrade F11R to smaller fragments, a mech-
nism that has been reported for other platelet proteins
21,25,26). It is also noteworthy that in its active confor-
ation, the F11R molecule is phosphorylated in its extra-
ellular domain (27). It is possible that in the setting of
cute MI (i.e., activated platelets, local release of adenosine
riphosphate from dense granules, elevated levels of pro-
eases such as thrombin) changes in phosphorylation/
ephosphorylation of the F11R molecule may result in
nhanced proteolysis of F11R with a subsequent decrease in
lasma levels.
tudy limitations. There are several limitations of this
tudy. First, the study was conducted in an exclusively male
opulation. Second, the study population was relatively
mall, and larger studies in both men and women are needed
o determine the factors that influence plasma F11R levels
n the absence of atherosclerotic disease. Third, the study
nvolved the measurement of a single baseline determination
f plasma F11R and it is unclear whether the results would
iffer substantially with repeated measurements that could
e affected by such factors as diurnal variation. Fourth, the
ack of intravascular ultrasound limits the ability to correlate
lasma F11R levels with the pathobiology of the vessel wall.
inally, the effects of concurrent illness on plasma F11R
evels are still unknown.
onclusions
he observations derived from this study are consistent with
he growing body of evidence demonstrating the importance of
latelets in the early phases of atherosclerosis and the critical
ole of F11R/JAM-A in triggering atherogenesis. The F11R
ppears to play a significant role in the development or
rogression of CAD. In particular, by virtue of its highorrelation with plasma TNF-alpha, F11R may be an impor-
ant mediator of the effects of inflammation on the vessel wall.
trategies that block F11R-mediated adhesion of platelets to
ndothelial cells may represent a novel approach to the treat-
ent and prevention of human atherosclerosis.
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